Myoclonus

Current Treatment Options in Neurology

Volumn 7, Issue 3, 2005, Pages 221-230

  Nirenberg, Melissa J ^b   Frucht, Steven J ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; ACETAZOLAMIDE; ALCOHOL; AMITRIPTYLINE; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZATROPINE; BOTULINUM TOXIN; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CENTRAL STIMULANT AGENT; CIMETIDINE; CLONAZEPAM; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; ESTROGEN; ETIRACETAM; FLUNARIZINE; FLUVOXAMINE; IMMUNOGLOBULIN; LAMOTRIGINE; LEVODOPA; LITHIUM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OPIATE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PRIMIDONE; PROTEINASE INHIBITOR; PSEUDOEPHEDRINE; QUINIDINE; RESERPINE; RIFAMPICIN; SEDATIVE AGENT; STEROID; SUMATRIPTAN; TEMAZEPAM; TETRABENAZINE; THIAMINE; THYROID HORMONE; TOPIRAMATE; TRIHEXYPHENIDYL; VALPROIC ACID; WARFARIN; ZONISAMIDE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; AKATHISIA; ALOPECIA; ANAPHYLAXIS; ANATOMICAL VARIATION; ANOREXIA; ANXIETY DISORDER; APLASTIC ANEMIA; ARTICLE; ATAXIA; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMA; CONFUSION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PREFERENCE; ELECTROLYTE DISTURBANCE; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERKINESIA; HYPERTENSIVE CRISIS; HYPERTHERMIA; INJURY; INSOMNIA; INVOLUNTARY MOVEMENT; LEUKOPENIA; LIVER NECROSIS; LIVER TOXICITY; MENTAL INSTABILITY; METABOLIC ACIDOSIS; MONOTHERAPY; MOTOR COORDINATION; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; MYOCLONUS; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PARKINSONISM; PLASMAPHERESIS; POLYPHARMACY; POLYURIA; PROGNOSIS; PSYCHOSIS; RESPIRATION DEPRESSION; SEIZURE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SWEAT GLAND DISEASE; SYMPTOMATOLOGY; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; TINNITUS; TREMOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 21244444301     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0015-1     Document Type: Article

References (23)

1. Marsden CD, Hallett M, Fahn S: The nosology and pathophysiology of myoclonus. Mov Disord 1982:196-248.
2. Frucht S: Myoclonus. Curr Treat Options Neurol 2000, 2:231-241.
3. Caviness JN, Brown P: Myoclonus: current concepts and recent advances. Lancet Neurol 2004, 3:598-607.
4. Easterford K, Clough P, Kellett M, et al.: Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004, 62:1435-1437.
5. Baig SM: Acetazolamide therapy improves action myoclonus in Ramsay Hunt Syndrome. J Neurol Sci 1997, 145:123-124.
6. Goetting MG: Catamenial exacerbation of action myoclonus: successful treatment with acetazolamide. J Neurol Neurosurg Psychiatry 1985, 48:1304-1305.
7. Koskiniemi M, Van Vleymen B, Hakamies L, et al.: Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998, 64:344-348.
8. Ikeda A, Shibasaki H, Tashiro K, et al.: Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord 1996, 11:691-700.
9. Genton P, Guerrini R, Remy C: Piracetam in the treatment of cortical myoclonus. Pharmacopsychiatry 1999, 32(Suppl 1):49-53.
10. Lynch BA, Lambeng N, Nocka K, et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
11. Keswani SC, Kossoff EH, Krauss GL, Hagerty C: Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry 2002, 73:457-458.
12. Krauss GL, Bergin A, Kramer RE, et al.: Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001, 56:411-412.
13. Frucht SJ, Louis ED, Chuang C, Fahn S: A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001, 57:1112-1114.
14. Magaudda A, Gelisse P, Genton P: Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004, 45:678-681.
15. Leppik IE: Zonisamide. Epilepsia 1999, 40(Suppl 5):S23-S29.
16. Wallace SJ: Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001, 23:277-283.
17. Kyllerman M, Ben-Menachem E: Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998, 29:109-114.
18. Siniscalchi A, Mancuso F, Russo E, et al.: Spinal myoclonus responsive to topiramate. Mov Disord 2004, 19:1380-1381.
19. Priori A, Bertolasi L, Pesenti A, et al.: Gamma-hydroxybutyric acid for alcohol-sensitive myoclonus with dystonia. Neurology 2000, 54:1706.
20. Defazio G, Abbruzzese G, Girlanda P, et al.: Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002, 59:418-420.
21. Liu X, Griffin IC, Parkin SG, et al.: Involvement of the medial pallidum in focal myoclonic dystonia: A clinical and neurophysiological case study. Mov Disord 2002, 17:346-353.
22. Kupsch A, Trottenberg T, Meissner W, Funk T: Neurostimulation of the ventral intermediate thalamic nucleus alleviates hereditary essential myoclonus. J Neurol Neurosurg Psychiatry 1999, 67:415-416.
23. Trottenberg T, Meissner W, Kabus C, et al.: Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001, 16:769-771.